Interview with Paul F. Austin

How long until Psychedelic Stocks Payoff?🍄🚀

To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

While researching a possible investment into psychedelic stocks, you have almost certainly heard the refrain of, “It’s a long-term investment.” I myself, in my many videos for The Psychedelic Investor and articles for PsychedelicSpotlight.com, have probably said this over 100 times.

And while the thesis for investing in psychedelic stocks is appealing, having a timeline clearer than “it’s a long term investment” is necessary before deciding whether it is worth the risk.

In this video, therefore, I endeavor to answer a big question: “When will psychedelic stocks provide a significant return on investment?”

Or, translated to Reddit-speak: when moon?

To start, I feel it’s necessary to give the warning that the answer may be never. To be clear, while I personally believe in the potential for psychedelic stocks such as MindMed (Nasdaq: MNMD, NEO: MMED) and Cybin (NYSE: CYBN, NEO: CYBN), the entire psychedelic medicines industry is inherently speculative and there is no guarantee of success. Yes, the science right now suggests that treatments such as MDMA therapy for PTSD and Ketamine therapy for addiction will disrupt the mental healthcare market, but this needs to be confirmed in larger studies.

There will be two separate turning points for psychedelic medicines and the companies that produce them: the legalization of the first psychedelic medicines, and the legalization of improved next-generation psychedelics.

The first will happen relatively soon.

#PsychedelicStocks #MindMed #Cybin

In today’s episode of the Psychedelic Spotlight Podcast, The Psychedelic Investor sits down with James Lanthier, CEO of Mindset Pharma (CSE: MSET, OTC: MSSTF).

Mindset Pharma is a psychedelic medicines company working on creating next-generation psychedelics to be used both in a therapy and microdosing setting. 

Mindset has three variations of psilocybin, the active ingredient in Magic Mushrooms. Two of these are being used in therapy settings, and one will be used for microdosing. Finally, the company has one family of compounds inspired by DMT and 5-MEO-DMT.

Excitingly, Mindset is moving towards beginning clinical trials in 2022.

On the day that the interview was recorded, Mindset released some major news; they are teaming up with Otsuka Pharmaceuticals to bring two of their drug families to market. As part of this deal, Mindset will receive $5 million USD upfront, and then Otsuka will also pay for some development costs. 

In the long term, this deal has great potential for Otsuka. 

To learn more about Mindset pharma and its stock, listen to the full interview. In it we attempt to answer questions such as:

Can psychedelics treat mental illnesses such as depression?

Are next-generation psychedelics better than the originals?

What is happening in the brain when a person takes psychedelics?

Enjoy the episode!

You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC market under the symbol $MSSTF.

*To learn more about Mindset Pharma visit their website: https://www.mindsetpharma.com/

#MindsetPharma #DMT #microdosing

ATAI IPOS TOMORROW! It’s finally happening! This Friday, on June 18th, 2021, the company I’ve been talking about for a while now, Atai Life Sciences, is set to IPO on the NASDAQ stock exchange, under ticker symbol “atai”.

This will automatically make Atai a runner for the title of the most advanced public psychedelic medicines company on the market.

So in this episode, we’ll discuss several things:

1. The details of the IPO
2. We’ll take a look at their financials
3. Look at Atai Life Sciences’ investment thesis
4. What I will be doing

Enjoy the episode!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Website: https://thepsychedelicinvestor.com/
editing: @themyaholy
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
https://www.atai.life/

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Atai #AtaiLifeSciences #AtaiIPO

It is an unfortunate fact that the world is dealing with a second hidden epidemic: The Opioid Crisis. Luckily, MindMed ( MMED/ MMEDF ) has a solution: 18-MC. This Psychedelic Medicines company, which may soon be uplisted to the Nasdaq, is testing it’s ibogaine derivative to heal those effected by opioid addiction, whether from fentanyl or doctors’ prescriptions. We may have a light at the end of the tunnel, and the Opioid Epidemic may be defeated. This makes MindMed one of the best stocks for 2021. How much could this be worth? Tune in to find out!

Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

Resources

https://www.cdc.gov/nchs/pressroom/podcasts/20190911/20190911.htm

https://www.ncbi.nlm.nih.gov/books/NBK541390/#:~:text=Morethan2millionpeople,diseasestraumaandsuicide.

https://www.hhs.gov/opioids/about-the-epidemic/opioid-crisis-statistics/index.html#:~:text=In2018anestimated10.3,and808000peopleusedheroin.&text=Appropriateprescribingofopioidsis,andsafetyofMedicarebeneficiaries.

https://www.ccsa.ca/opioids#:~:text=Canadaisinthemidst,publichealthandsafetyconcern.

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.17477

https://www.publichealthontario.ca/-/media/documents/o/2020/opioid-mortality-covid-surveillance-report.pdf?la=en

https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/opioid-addiction

https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery

https://preprod.drugfree.org/article/relapse-overdose/

https://mindmed.co/psychedelic-inspired/#scroll_section-1

https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine

https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine

https://s3.ca-central-1.amazonaws.com/ibosafe-pdf-resources/Ibogaine/Treating+drug+dependence+with+the+aid+of+ibogaine_a+retrospective+study.pdf

https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine

https://thethirdwave.co/psychedelics/ibogaine/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382526/#:~:text=Theantiaddictiondrugibogainecertainlyaffectstheheartand,ibogaine’spotentiallylifethreateningcardiotoxicity.

https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf

https://www.ibogainealliance.org/18-mc/

https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf

#MindMed #MMED #MMEDF #MindMedNews #OpioidEpidemic #OpioidCrisis #MindMedStock #18MC #18-MC #PsychedelicStocks